Transcriptional regulation of osteopontin and the metastatic phenotype: Evidence for a Ras-activated enhancer in the human OPN promoter

Clinical and Experimental Metastasis

Volumn 20, Issue 1, 2003, Pages 77-84

  Denhardt, David T ^a   Mistretta, Devra ^a   Chambers, Ann F ^b   Krishna, Shuba ^a   Porter, Joseph F ^a   Raghuram, Srilatha ^a   Rittling, Susan R ^a  

^a RUTGERS UNIVERSITY   (United States)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

Cell survival; Gel shifts; Gene expression; Knockout; Osteopontin; Tcf 4

Indexed keywords

CALCIUM ION; OSTEOPONTIN; RAS PROTEIN; TRANSCRIPTION FACTOR;

ASTROCYTE; BINDING SITE; CANCER CELL; CARCINOGENESIS; CORRELATION ANALYSIS; DISEASE MARKER; ENHANCER REGION; FIBROBLAST; GENE SEQUENCE; GENETIC TRANSCRIPTION; HUMAN; METASTASIS; NONHUMAN; PHENOTYPE; PROMOTER REGION; PROTEIN FUNCTION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; CELL ADHESION MOLECULES; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; ENHANCER ELEMENTS (GENETICS); GENE EXPRESSION REGULATION; GENES, RAS; HUMANS; MICE; MICE, KNOCKOUT; NEOPLASM METASTASIS; NEOPLASMS; OSTEOPONTIN; PROMOTER REGIONS (GENETICS); SIALOGLYCOPROTEINS; TRANSCRIPTION, GENETIC;

EID: 0037220080     PISSN: 02620898     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1022550721404     Document Type: Review

References (96)

1. Senger DR, Perruzzi CA, Gracey CF et al. Secreted phosphoproteins associated with neoplastic transformation: Close homology with plasma proteins cleaved during blood coagulation. Cancer Res 1988; 48: 5770-4.
2. Chambers AF, Tuck AB. Ras-responsive genes and tumor metastasis. Crit Rev Oncogen 1993; 4: 95-114.
3. Denhardt DT, Guo X. Osteopontin a protein with diverse functions. FASEB J 1993; 7: 1475-82.
4. Oates AJ, Barraclough R, Rudland PS. The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 1997; 17: 1-15.
5. Uede T, Katagiri Y, Iizuka J et al. Osteopontin, a coordinator of host defense system: A cytokine or an extracellular adhesive protein? Microbiol Immunol 1997; 41: 641-8.
6. Rittling SR, Denhardt DT. Osteopontin function in pathology: Lessons from OPN-deficient mice. Expt Nephrology 1999; 7: 103-13.
7. Noda M, Denhardt DT. Osteopontin. In Bilezikian JP, Raisz LG, Rodan GA (eds): Principles of Bone Biology, 2nd ed. San Diego: Academic Press 2002.
8. Chabas D, Baranzini SE, Mitchell D et al. The influence of the proinflammatory cytokine, osteopontin, on autoimmune demyelinating disease. Science 2001; 294: 1731-5.
9. Yumoto K, Ishijima M, Rittling SR et al. Osteopontin deficiency protects joints against destruction in anti-type II collagen antibody-induced arthritis in mice. Proc Natl Acad Sci USA 2002; 99: 4556-61.
10. Giachelli CM, Steitz S. Osteopontin: A versatile regulator of inflammation and biomineralization. Matrix Biol 2000; 19: 615-22
11. Weber GF. The metastasis gene osteopontin: A candidate target for cancer therapy. Biochim Biophys Acta 2001; 1552: 61-85
12. Denhardt DT, Noda M, O'Regan AW et al. Osteopontin- a means to cope with environmental insults: Regulation of inflammation tissue remodeling and cell survival. J Clin Invest 2001; 107: 1055-61.
13. Tuck AB, Chambers AF. The role of osteopontin in breast cancer: Clinical and experimental studies. J Mammary Gland Biol Neoplasia 2001; 6: 419-29
14. Furger KA, Menon RK, Tuck AB et al. The functional and clinical roles of osteopontin in cancer and metastasis. Curr Mol Med 2001; 1: 621-32
15. Rittling SR, Chen Y, Feng F, Wu Y. Tumor-derived osteopontin is soluble, not matrix associated. J Biol Chem 2002; 277: 9175-82.
16. Katagiri YU, Sleeman J, Fujii H et al. CD44 variants but not CD44s cooperate with betal-containing integrins to permit cells to bind to osteopontin independently of arginine-glycine-aspartic acid, thereby stimulating cell motility and chemotaxis. Cancer Res 1999; 59: 219-26.
17. Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med 2000; 11: 279-303.
18. Suzuki K, Zhu B, Rittling SR et al. Colocalization of intracellular osteopontin with CD44 is associated with migration, cell fusion, and resorption in osteoclasts. J Bone Miner Res 2002; 17:1486-97.
19. Denhardt DT, Lopez CA, Rollo EE et al. Osteopontin-induced modifications of cellular functions. Ann NY Acad Sci 1995; 760: 127-42.
20. Noiri E, Dickman K, Miller F et al. Reduced tolerance to acute renal ischemia in mice with a targeted disruption of the osteopontin gene. Kidney Int 1999; 56: 74-82
21. 3 integrin-induced endothelial cell survival. J Cell Biol 1998; 141: 1083-93.
22. Lin Y-H, Yang-Yen H-F. The osteopontin-CD44 survival signal involves activation of the phosphatidylinositol-3-kinase/Akt signaling pathway. J Biol Chem 2001; 276: 46024-30.
23. Khan SA, Lopez-Chua CA, Zhang J, Fisher LW, Sorensen ES, Denhardt DT. Soluble osteopontin inhibits apoptosis of adherent endothelial cells deprived of growth factors. J Cellul Biochem 2002; 85: 728-36.
24. Senger DR, Asch BB, Smith BD et al. A secreted phosphoprotein marker for neoplastic transformation of both epithelial and fibroblastic cells. Nature 1983; 302: 714-5.
25. Brown LF, Papadopoulos-Sergiou A, Berse B et al. Osteopontin expression and distribution in human carcinomas. Am J Pathol 1994; 145: 610-23.
26. Bellahcene A, Castronovo V. Increased expression of osteonectin and osteopontin two bone matrix proteins in human breast cancer. Am J Pathol 1996; 146: 95-100
27. Casson AG, Wilson SM, McCart JA et al. Ras mutation and expression of the ras-regulated genes osteopontin and cathepsin L in human esophageal cancer. Int J Cancer 1997; 72: 739-45.
28. Gillespie MT, Thomas RJ, Zhou PU et al. Calcitonin receptors bone sialoprotein and osteopontin are expressed in primary breast cancers. Int J Cancer 1997; 10: 812-815.
29. Tuck AB, O'Malley FP, Singhal H et al. Osteopontin expression in a group of lymph node negative breast cancer patients. Int J Cancer 1998; 79: 502-8
30. Sung V, Gilles C, Murray A et al. The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits invasive and metastatic phenotype. Exp Cell Res 1998; 241: 273-84.
31. Sharp JA, Sung V. Slavin J et al. Tumor cells are the source of osteopontin and bone sialoprotein expression in human breast cancer. Lab Invest 1999; 79: 869-77
32. Price JE, Polyzos A, Zhang RD et al. Tumorigenicity and metastasis of human breast carcinoma cell lines in nude mice. Cancer Res 1990; 50: 717-21
33. Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991; 11: 204-15.
34. Price JE. Metastasis from human breast cancer cell lines. Breast Cancer Res Treat 1996; 39: 93-102.
35. Bautista DS, Xuan JW, Hera C et al. Inhibition of Arg-Gly-Asp (RGD)-mediated cell adhesion to osteopontin by a monoclonal antibody against osteopontin. J Biol Chem 1994; 269: 23280-5.
36. Tuck AB, Arsenault DM, O'Malley FP et al. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells. Oncogene 1999; 18: 4237-46.
37. Yoneda T, Williams PJ, Niewolna M. Promotion of angiogenesis and enhancement of breast cancer metastasis to bone. Bone 1998; 23/5S: S201.
38. Mukhopadhyay R, Price JE. Stable expression of antisense osteopontin inhibits the growth of human breast cancer cells. Proc Am Assoc Cancer Res 1999; 40: 448.
39. Senger DR, Perruzzi CA, Papadopoulos A. Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. Anticancer Res 1989; 9: 1291-300
40. Chambers AF, Tuck AB. Osteopontin: A Ras-regulated gene that contributes to tumor metastasis. In Welch DR (ed): Cancer Metastasis-Related Genes. Dordrecht, The Netherlands: Kluwer Academic Publishers 2002; 231-46.
41. Hwang S-M, Lopez CA, Heck DE et al. Osteopontin inhibits induction of nitric oxide synthase gene expression by inflammatory mediators in mouse kidney epithelial cells. J Biol Chem 1994; 269: 711-5.
42. Rollo EE, Laskin DL, Denhardt DT Osteopontin inhibits nitric oxide production and cytotoxicity by activated RAW2647 macrophages. J Leuk Biol 1996; 60: 397-404.
43. Scott JA, Weir ML, Wilson SM et al. Osteopontin inhibits inducible nitric oxide synthase activity in rat vascular tissue. Am J Physiol 1998; 275: H2258-65.
44. Denhardt DT, Chambers AF. Overcoming obstacles to metastasis - defenses against host defenses: Osteopontin (OPN) as a shield against attack by cytotoxic host cells. J Cell Biochem 1994; 56: 48-51
45. Yue TL, McKenna PJ, Ohlstein EH et al. Osteopontin-stimulated vascular smooth muscle cell migration is mediated by β3 integrin. Exp Cell Res 1994; 214: 459-64.
46. 3 in smooth muscle cell migration to osteopontin in vitro. J Clin Invest 1995; 95: 713-24
47. Senger DR, Perruzzi CA. Cell migration promoted by a potent GRGDS-containing thrombin-cleavage fragment of osteopontin. Biochim Biophys Acta 1996; 1314: 13-24.
48. Weintraub AS, Giachelli CM, Krauss RS et al. Autocrine secretion of osteopontin by vascular smooth muscle cells regulates their adhesion to collagen gels. Am J Path 1996; 149: 259-72
49. Tuck AB, Elliott BE, Hota C et al. Osteopontin-induced integrin-dependent migration of human mammary epithelial cells involves activation of the hepatocyte growth factor receptor. J Cell Biochem 2000; 78: 465-75
50. Tuck AB, Hota C, Chambers AF. Osteopontin-induced increase in human mammary epithelial cell invasiveness is urokinase (uPa)-dependent. Breast Cancer Res Treat 2001; 70: 197-204
51. Takahashi F, Akutagawa S, Fukumoto H et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 2002; 98: 707-12
52. Chambers AF, Wilson SM, Kerkvleit N et al. Osteopontin expression in lung cancer. Lung Cancer 1996; 15: 311-23.
53. Rudland PS, Platt-Higgins A, El-Tanani M et al. Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Res 2002; 62: 3417-27
54. Kim JH, Skates SJ, Uede T et al. Osteopontin as a potential diagnostic biomarker for ovarian cancer. JAMA 2002; 287: 1671-9.
55. Gotoh M, Sakamoto M, Kanetaka K et al. Overexpression of osteopontin in hepatocellular carcinoma. Pathol Int 2002; 52: 19-24.
56. Agrawal D, Chen T, Irby R et al. Osteopontin identified as lead marker of colon cancer progression, using pooled sample expression profiling. J Natl Cancer Inst 2002; 94: 513-21.
57. Bautista DS, Saad Z, Chambers AF et al. Quantification of osteopontin in human plasma with an ELISA: Basal levels in pre- and postmenopausal women. Clin Biochem 1996; 29: 231-9.
58. Singhal H, Bautista DS, Tonkin KS et al. Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clin Cancer Res 1997; 3: 605-11.
59. Hotte SJ, Winquist, EW, Stitt L et al. Plasma osteopontin: Associations with survival and metastasis to bone in men with hormone refractory prostate cancer. Cancer, 2002; 95: 506-512.
60. Fedarko NS, Fohr B, Robey PG et al. Factor H binding to bone sialoprotein and osteopontin enables tumor cell evasion of complement-mediated attack. J Biol Chem 2000; 275: 16666-72.
61. Fedarko NS, Jain A, Karadag A et al. Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 2001; 7: 4060-6.
62. O'Regan A, Fleming C. Comment on: JAMA 2002, 287: 1671-9. Osteopontin as a biomarker for ovarian cancer. JAMA 2002; 287: 3208-10.
63. O'Regan A, Fleming C. Comment on: JAMA 2002, 287: 1671-9. Osteopontin as a biomarker for ovarian cancer. JAMA 2002; 287: 3208-10.
64. Crawford HC, Matrisian LM, Liaw L. Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. Cancer Res 1998; 58: 5206-15.
65. Feng F, Rittling SR. Mammary tumor development in MMTV-c-myc/MMTV-v-Ha-ras transgenic mice is unaffected by osteopontin deficiency. Breast Cancer Res Treat 2000; 63: 71-9.
66. Wu Y, Denhardt DT, Rittling SR. Osteopontin expression is required for full expression of the transformed phenotype by the Ras oncogene. Br J Cancer 2000; 83: 156-63.
67. Nemoto H, Rittling SR, Yoshitake H et al. Osteopontin deficiency reduces experimental tumor cell metastasis to bone and soft tissues. J Bone Miner Res 2001; 16: 652-9.
68. Orphanides G, Reinberg DA. Unified theory of gene expression. Cell 2002; 108: 439-52.
69. Hunter T. Oncoprotein networks. Cell 1997; 88: 333-46.
70. Webb CP, Vande Woude GF, Genes that regulate metastasis and angiogenesis. J Neurooncol 2000; 50: 71-87.
71. Welch DR, Steeg PS, Rinker-Schaeffer CW. Molecular biology of breast cancer metastasis. Genetic regulation of human breast carcinoma metastasis. Breast Cancer Res 2000; 2: 408-16.
72. Denhardt DT, Noda M. Osteopontin expression and function: Role in bone remodeling. J Cell Biochem 1998; Suppl 30/31: 92-102.
73. Craig AM, Bowden GT, Chambers AF et al. Secreted phosphoprotein mRNA is induced during multistage carcinogenesis in mouse skin and correlates with the metastatic potiential of murine fibroblasts. Int J Cancer 1990; 46: 133-7.
74. Yoon JW, Kita Y, Frank DJ et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J Biol Chem 2002; 277: 5548-55.
75. Davies BR, Barraclough R, Rudland PS. Induction of metastatic ability in a stably diploid benign rat mammary epithelial cell line by transfection with DNA from human malignant breast carcinoma cell lines. Cancer Res 1994; 54: 2785-93.
76. Oates AJ, Barraclough R, Rudland PS. The identification of osteopontin as a metastasis-related gene product in a rodent mammary tumour model. Oncogene 1996; 13: 97-104.
77. Chen H, Ke Y, Oates AJ et al. Isolation of and effector for metastasis-inducing DNAs from a human metastatic carcinoma cell line. Oncogene 1997; 14: 1581-8.
78. El-Tanani M, Barraclough R, Wilkinson MC et al. Regulatory region of metastasis-inducing DNA is the binding site for T cell factor-4. Oncogene 2001; 20: 1793-7.
79. El-Tanani M, Barraclough R, Wilkinson MC et al. Metastasis-inducing DNA regulates the expression of the osteopontin gene by binding the transcription factor Tcf-4. Cancer Res 2001; 61: 5619-29
80. Wang D, Yamamoto S, Hijiya N et al. Transcriptional regulation of the human osteopontin promoter: Functional analysis and DNA-protein interactions. Oncogene 2000; 19: 5801-9.
81. Malyankar UM, Hanson R, Schwartz SM et al. Upstream stimulatory factor 1 regulates osteopontin expression in smooth muscle cells. Exp Cell Res 1999; 250:535-47.
82. Bos JL. Ras oncogenes in human cancer: A review. Cancer Res 1989; 49: 4682-9
83. Varghese HJ, Davidson MT. MacDonald IC et al. Activated ras regulates the proliferation/apoptosis balance and early survival of developing micrometastases. Cancer Res 2002; 62: 887-91
84. Rak J, Kerbel RS. Ras regulation of vascular endothelial growth factor and angiogenesis. Methods Enzymol 2001; 333: 267-83
85. Guo X, Zhang YP, Mitchell DA et al. Identification of a ras-activated enhancer in the mouse osteopontin gene and its interaction with a putative ETS-related transcription factor whose activity correlates with the metastatic potential of the cell. Mol Cell Biol 1995; 15: 476-87.
86. Craig AM, Denhardt DT. The murine gene encoding secreted phosphoprotein (osteopontin): Promoter structure activity and induction in vivo by estrogen and progesterone. Gene 1991; 100: 163-71.
87. Zhang Q, Wrana JL, Sodek J. Characterization of the promoter region of the porcine opn (osteopontin secreted phosphoprotein 1) gene. Eur J Biochem 1992; 207: 649-59.
88. Hijiya N, Setoguchi M, Matsuura K et al. Cloning and characterization of the human osteopontin gene and its promoter. Biochem J 1994; 303: 255-62.
89. Rafidi K, Simkina I, Johnson E et al. Characterization of the chicken osteopontin-encoding gene. Gene 1994; 140: 163-9.
90. Ridall AL, Daane EL, Dickinson DP et al. Characterization of the rat osteopontin gene. Evidence for two vitamin D response elements. Ann NY Acad Sci 1995; 760: 59-66.
91. Webb CP, van Aelst L, Wigler MH et al. Signaling pathways in Rasmediated tumorigenicity and metastasis. Proc Natl Acad Sci USA 1998; 95: 8773-8
92. Morishita R, Higaki J, Tomita N et al. Application of transcription factor 'decoy' strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998; 82: 1023-8.
93. Tomita S, Tomita N, Yamada T et al. Transcription factor decoy to study the molecular mechanism of negative regulation of renin gene expression in the liver in vivo. Circ Res 1999; 84: 1059-66.
94. Van Golen KL, Wu Z-F, Qial T et al. RhoC GTPase, a novel transforming oncogene for human mammary epithelial cells that partially recapitulates the inflammatory breast cancer phenotype. Cancer Res 2000; 60: 5832-8
95. Tuteja R, Tuteha N. Ku Autoantigen: A multifactorial DNA-binding protein. Crit Rev Biochem Mol Biol 2000; 35: 1-33.
96. Singh H, Sen R, Baltimore D et al. A nuclear factor that binds to a conserved sequence motif in transcriptional control elements of immunoglobulin genes. Nature 1986; 319: 154-8.